Portfolio Position: Teva Pharmaceuticals $TEVA
Teva Pharmaceuticals 
TEVA has shed over 50% of its value following its 6.1B impairment charge and 75% dividend slash in its latest quarterly report.
Pros:
- The company continues to expect double digit sales growth from its recent Actavis acquisition from Allergan AGN.
- Teva expects over 1,500 new drugs to launch in 2017, with over 900 drugs still pending approvals.
- The company is divesting its non-core organic revenue drivers, expected to bring in over 55B in 2017 and boost margins.
- Aggressive cost cutting, saving over 1.6B annually is expected to boost Net Income and Margins.
Risks:
- Teva's blockbuster drug Copaxone is under competitive pressure, losing market share in 2017 & is expected to continue in 2018.
- Sentiment: The company still trades in a highly retail environment being effected by mass hysteria, boding bad for share price.
Targets:
I initiate TEVA with a $30 PT for the next 12 months, throughout 2018.
For the full review: seekingalpha.com/article/4103038-teva-complete-overview
TEVA has shed over 50% of its value following its 6.1B impairment charge and 75% dividend slash in its latest quarterly report.Pros:
- The company continues to expect double digit sales growth from its recent Actavis acquisition from Allergan AGN.
- Teva expects over 1,500 new drugs to launch in 2017, with over 900 drugs still pending approvals.
- The company is divesting its non-core organic revenue drivers, expected to bring in over 55B in 2017 and boost margins.
- Aggressive cost cutting, saving over 1.6B annually is expected to boost Net Income and Margins.
Risks:
- Teva's blockbuster drug Copaxone is under competitive pressure, losing market share in 2017 & is expected to continue in 2018.
- Sentiment: The company still trades in a highly retail environment being effected by mass hysteria, boding bad for share price.
Targets:
I initiate TEVA with a $30 PT for the next 12 months, throughout 2018.
For the full review: seekingalpha.com/article/4103038-teva-complete-overview
Disclaimer
The information and publications are not meant to be, and do not constitute, financial, investment, trading, or other types of advice or recommendations supplied or endorsed by TradingView. Read more in the Terms of Use.